EA202192860A1 - Сиалилированные гликопротеины - Google Patents
Сиалилированные гликопротеиныInfo
- Publication number
- EA202192860A1 EA202192860A1 EA202192860A EA202192860A EA202192860A1 EA 202192860 A1 EA202192860 A1 EA 202192860A1 EA 202192860 A EA202192860 A EA 202192860A EA 202192860 A EA202192860 A EA 202192860A EA 202192860 A1 EA202192860 A1 EA 202192860A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mechanical stress
- hsigg
- resistant
- sialylated glycoproteins
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Описаны фармацевтические препараты, содержащие гиперсиалилированные иммуноглобулины (hsIgG). Препараты устойчивы к механическому воздействию. Описанные в данном документе фармацевтические композиции обеспечивают фармацевтически приемлемые композиции hsIgG, которые устойчивы к механическому воздействию (например, если состав подвергается механическому воздействию, такому как встряхивание, например, во время транспортировки, при этом не происходит образования значительного количества невидимых частиц) и которые, таким образом, можно транспортировать и обрабатывать в жидкой форме.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962836016P | 2019-04-18 | 2019-04-18 | |
PCT/US2020/028863 WO2020215021A1 (en) | 2019-04-18 | 2020-04-17 | Sialylated glycoproteins |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202192860A1 true EA202192860A1 (ru) | 2021-12-23 |
Family
ID=72837963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202192860A EA202192860A1 (ru) | 2019-04-18 | 2020-04-17 | Сиалилированные гликопротеины |
Country Status (20)
Country | Link |
---|---|
US (1) | US20220211849A1 (ru) |
EP (1) | EP3955962A4 (ru) |
JP (1) | JP2022529168A (ru) |
KR (1) | KR20220002963A (ru) |
CN (1) | CN113795275A (ru) |
AU (1) | AU2020259492A1 (ru) |
BR (1) | BR112021020509A8 (ru) |
CA (1) | CA3137101A1 (ru) |
CL (1) | CL2021002668A1 (ru) |
CO (1) | CO2021013926A2 (ru) |
CR (1) | CR20210521A (ru) |
EA (1) | EA202192860A1 (ru) |
EC (1) | ECSP21078309A (ru) |
IL (1) | IL287306A (ru) |
JO (1) | JOP20210281A1 (ru) |
MX (1) | MX2021012710A (ru) |
PE (1) | PE20220383A1 (ru) |
SG (1) | SG11202110942SA (ru) |
WO (1) | WO2020215021A1 (ru) |
ZA (1) | ZA202109184B (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7266108B2 (ja) | 2019-02-18 | 2023-04-27 | イーライ リリー アンド カンパニー | 治療用抗体製剤 |
EP4248218A1 (en) | 2020-11-20 | 2023-09-27 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0411103B1 (pt) * | 2003-06-09 | 2019-01-15 | A Mcintyre John | método, e, método de obtenção e isolamento de um autoanticorpo de um fluido biológico contendo anticorpo ou de um extrato de fluido biológico contendo anticorpo |
EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
AU2006278573A1 (en) * | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
KR101464032B1 (ko) * | 2009-05-27 | 2014-11-27 | 백스터 인터내셔널 인코포레이티드 | 피하 사용을 위한 고 농축 면역글로불린 제제의 제조 방법 |
FR2961107B1 (fr) * | 2010-06-15 | 2012-07-27 | Lab Francais Du Fractionnement | Composition d'immunoglobulines humaines stabilisee |
EP2900264A4 (en) * | 2012-09-26 | 2016-05-25 | Momenta Pharmaceuticals Inc | GLYKOPROTEINZUBEREITUNGEN |
ES2802274T3 (es) * | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Glicoproteínas sialiladas |
CA2908407C (en) * | 2013-05-29 | 2022-06-14 | F. Hoffmann-La Roche Ag | Quantitative control of sialylation |
AU2018207367B2 (en) * | 2017-01-11 | 2024-02-15 | Celltrion Inc. | Stable Liquid Formula |
-
2020
- 2020-04-17 CN CN202080029642.8A patent/CN113795275A/zh active Pending
- 2020-04-17 WO PCT/US2020/028863 patent/WO2020215021A1/en active Application Filing
- 2020-04-17 CA CA3137101A patent/CA3137101A1/en active Pending
- 2020-04-17 MX MX2021012710A patent/MX2021012710A/es unknown
- 2020-04-17 JO JOP/2021/0281A patent/JOP20210281A1/ar unknown
- 2020-04-17 US US17/602,156 patent/US20220211849A1/en active Pending
- 2020-04-17 JP JP2021561870A patent/JP2022529168A/ja active Pending
- 2020-04-17 BR BR112021020509A patent/BR112021020509A8/pt unknown
- 2020-04-17 AU AU2020259492A patent/AU2020259492A1/en active Pending
- 2020-04-17 PE PE2021001732A patent/PE20220383A1/es unknown
- 2020-04-17 EP EP20792022.4A patent/EP3955962A4/en active Pending
- 2020-04-17 SG SG11202110942SA patent/SG11202110942SA/en unknown
- 2020-04-17 EA EA202192860A patent/EA202192860A1/ru unknown
- 2020-04-17 CR CR20210521A patent/CR20210521A/es unknown
- 2020-04-17 KR KR1020217037216A patent/KR20220002963A/ko unknown
-
2021
- 2021-10-12 CL CL2021002668A patent/CL2021002668A1/es unknown
- 2021-10-15 CO CONC2021/0013926A patent/CO2021013926A2/es unknown
- 2021-10-17 IL IL287306A patent/IL287306A/en unknown
- 2021-10-22 EC ECSENADI202178309A patent/ECSP21078309A/es unknown
- 2021-11-17 ZA ZA2021/09184A patent/ZA202109184B/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202110942SA (en) | 2021-11-29 |
EP3955962A1 (en) | 2022-02-23 |
CN113795275A (zh) | 2021-12-14 |
ECSP21078309A (es) | 2021-11-30 |
ZA202109184B (en) | 2023-04-26 |
IL287306A (en) | 2021-12-01 |
PE20220383A1 (es) | 2022-03-18 |
US20220211849A1 (en) | 2022-07-07 |
CL2021002668A1 (es) | 2022-05-27 |
JP2022529168A (ja) | 2022-06-17 |
CA3137101A1 (en) | 2020-10-22 |
CR20210521A (es) | 2022-04-01 |
MX2021012710A (es) | 2021-11-12 |
JOP20210281A1 (ar) | 2023-01-30 |
AU2020259492A1 (en) | 2021-11-11 |
EP3955962A4 (en) | 2022-12-14 |
WO2020215021A1 (en) | 2020-10-22 |
KR20220002963A (ko) | 2022-01-07 |
BR112021020509A8 (pt) | 2023-01-10 |
CO2021013926A2 (es) | 2021-10-29 |
BR112021020509A2 (pt) | 2022-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
EA201992377A1 (ru) | Стабильная композиция антитела | |
EA202192860A1 (ru) | Сиалилированные гликопротеины | |
MX2020007853A (es) | Composiciones farmaceuticas para el tratamiento de fibrosis quistica. | |
MX2020007697A (es) | Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra grupo de diferenciacion 3 (cd3) y grupo de diferenciacion 20 (cd20) y sus usos. | |
MX2018013215A (es) | Composicion farmaceutica. | |
EA201990831A1 (ru) | Смесительная система для получения косметического продукта и косметическая капсула | |
PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
MX2021001272A (es) | Composiciones de bismuto-tiol y metodos de uso. | |
MX2020014031A (es) | Proteinas heterodimericas y usos de las mismas. | |
CL2017003208A1 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
MX2022001721A (es) | Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos. | |
WO2015058173A8 (en) | Stable solid units and methods of making the same | |
PH12021550226A1 (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
MX2020009275A (es) | Composiciones de anticuerpo anti-pd-1. | |
ZA202106914B (en) | Process for making stable bacterial extracts and their use as pharmaceuticals | |
EA202091095A1 (ru) | Пероральная доставка пептидных аналогов glp-1 | |
EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
MX2021011137A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33. | |
MX2022006130A (es) | Composiciones inyectables de ácido ursodeoxicólico. | |
SG10201807034XA (en) | A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease | |
MX2022005317A (es) | Prevencion de formacion de particulas visibles en soluciones acuosas de proteina. | |
EA202090568A1 (ru) | Составы копанлисиба | |
MX2022005044A (es) | Formulacion de anticuerpo que contiene crizanlizumab. |